United Therapeutics (UTHR) Expected to Release Earnings on Wednesday

United Therapeutics (NASDAQ:UTHR) is expected to issue its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect United Therapeutics to announce earnings of $6.01 per share and revenue of $781.18 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 9:00 AM ET.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.86 by $0.41. The company had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. During the same period in the prior year, the firm earned $6.41 earnings per share. The firm’s quarterly revenue was down 1.9% on a year-over-year basis. On average, analysts expect United Therapeutics to post $26.07 EPS for the current fiscal year and $30.36 EPS for the next fiscal year.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $591.20 on Wednesday. The firm has a fifty day moving average of $522.90 and a 200-day moving average of $528.93. United Therapeutics has a 52-week low of $409.07 and a 52-week high of $609.35.

United Therapeutics declared that its board has approved a share repurchase program on Thursday, October 22nd that permits the company to buy back $2 billion in shares. This repurchase authorization permits the biotechnology company to buy up to 8.3% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s management believes its shares are undervalued.

Insider Activity at United Therapeutics

In other news, CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $526.96, for a total transaction of $5,006,120.00. Following the sale, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $170,968,483.28. This represents a 2.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 401,528 shares of company stock worth $209,465,456 over the last three months. 8.60% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have issued reports on UTHR shares. JPMorgan Chase & Co. boosted their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Royal Bank Of Canada cut their target price on shares of United Therapeutics from $708.00 to $697.00 and set an “outperform” rating on the stock in a research note on Thursday, October 22nd. Cantor Fitzgerald restated an “overweight” rating and set a $850.00 target price on shares of United Therapeutics in a report on Monday. Jefferies Financial Group reaffirmed a “buy” rating and set a $728.00 price target on shares of United Therapeutics in a research report on Wednesday, October 14th. Finally, Weiss Ratings downgraded United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, August 27th. Twelve analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and an average target price of $666.50.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.